Targeting HER2-positive breast cancer cells by a combination of dasatinib and BMS-202: Insight into the molecular pathways

Recent investigations have reported the benefits of using a tyrosine kinase inhibitor, dasatinib (DA), as well as programmed death-ligand 1 (PD-L1) inhibitors in the management of several solid tumors, includi...

Source: Cancer Cell International - March 2, 2024 Category: Cancer & Oncology Authors: Hadeel Kheraldine, Ishita Gupta, Farhan Sachal Cyprian, Semir Vranic, Halema F. Al-Farsi, Maysaloun Merhi, Said Dermime and Ala-Eddin Al Moustafa Tags: Research Source Type: research